

- 2 Reinheimer, T. et al. (1995) *Am. J. Physiol.* 270, L722–L728
- 3 Klapproth, H. et al. (1997) *Naunyn-Schmiedeberg's Arch. Pharmacol.* 355, 515–523
- 4 Wessler, I., Kirkpatrick, C. J. and Racké, K. (1998) *Pharmacol. Ther.* 77, 59–79
- 5 Reinheimer, T. et al. (1998) *Eur. J. Pharmacol.* 349, 277–284
- 6 Grando, S. A. (1997) *J. Invest. Dermatol. Symp. Proc.* 2, 41–48
- 7 Sastry, B. V. R. and Sadavongvivad, C. (1979) *Pharmacol. Rev.* 30, 65–132
- 8 Klapproth, H., Racké, K. and Wessler, I. (1994) *Naunyn-Schmiedeberg's Arch. Pharmacol.* 349 (Suppl.), R72
- 9 Klapproth, H., Racké, K. and Wessler, I. (1998) *Naunyn-Schmiedeberg's Arch. Pharmacol.* 357, 472–475
- 10 Reinheimer, T., Baumgärtner, D., Höhle, K.-D., Racké, K. and Wessler, I. (1997) *Am. J. Resp. Crit. Care Med.* 156, 389–395
- 11 Wessler, I., Hellwig, D. and Racké, K. (1990) *Naunyn-Schmiedeberg's Arch. Pharmacol.* 342, 387–393
- 12 Racké, K., Bähring, A., Brunn, G., Elsner, M. and Wessler, I. (1991) *Br. J. Pharmacol.* 103, 1213–1217
- 13 Racké, K. et al. (1992) *Am. Rev. Resp. Dis.* 146, 1182–1186
- 14 Starke, K., Göthert, M. and Kilbinger, H. (1989) *Physiol. Rev.* 69, 864–989
- 15 Fuder, H. and Muscholl, E. (1995) *Rev. Physiol. Biochem. Pharmacol.* 126, 265–412
- 16 Brunn, G., Wessler, I. and Racké, K. (1995) *Br. J. Pharmacol.* 116, 191–198
- 17 Racké, K., Brunn, G., Elsner, M. and Wessler, I. (1993) *Naunyn-Schmiedeberg's Arch. Pharmacol.* 348, 21–27
- 18 Wessler, I. et al. (1994) *Br. J. Pharmacol.* 113, 1221–1230

## Folkerts and Nijkamp reply

*Airway epithelium: more than just a source for epithelium-derived relaxing factors!*

We thank Ignaz Wessler, Charles Kirkpatrick and Kurt Racké for their interest in our review<sup>1</sup>. We apologize for not including the references of these authors when mentioning that acetylcholine can be released by the epithelium and that the epithelium contains the synthesizing enzyme choline acetyltransferase<sup>2–5</sup>. However, as pointed out in the abstract, our aim was to focus on the pharmacological relevance of the putative epithelium-derived relaxing factors prostaglandin E<sub>2</sub> and NO in the modulation of airway tone. Further, special attention was paid to the role of both epithelium-derived relaxing factors in the development of airway hyperresponsiveness in animal models and in patients with asthma.

Acetylcholine, although released by the epithelium, is a contractile factor – if it modulates airway function in a positive way, it does so by an indirect action<sup>5</sup>. By contrast, our review highlighted the direct actions of prostaglandin E<sub>2</sub> and NO on smooth muscle<sup>1</sup>. This was also the reason why the action of epithelium-derived relaxing factors on the release of autonomic neurotransmitters (neuro-epithelium interaction) was not discussed. Moreover, we were limited in the amount of text and the number of references that we could include. Nevertheless, the timely finding that epithelium can synthesize and release acetylcholine was so interesting that we presented

it as a fact together with the ability of the epithelium to release mucus, cytokines, and chemokines as well as the ability of the epithelium to metabolize histamine and neuropeptides (all without references).

For clarity, it should be pointed out that acetylcholine is probably not the only neurotransmitter, nor is it the only contractile mediator, released by the epithelium. In rat trachea, removal of the epithelium reduced the tissue content of noradrenaline by about 30%. Moreover, the overflow of noradrenaline evoked by electrical stimulation of epithelium-denuded tracheas was reduced by 70–80%, which suggests that the epithelium was involved in the release of noradrenaline<sup>6</sup>. It is well recognized that arachidonic acid can be metabolized by airway epithelial cells<sup>7,8</sup> and that these products can influence airway tone and reactivity<sup>9</sup>. Recent evidence showed that the inherent tone of the human bronchus was maintained by a balance between 5-lipoxygenase and cyclooxygenase products formed by the epithelium<sup>10</sup>. Vasopressin and substance P immunoreactivity in cultured and intact epithelium from rabbit tracheae has also been demonstrated<sup>11</sup>. In addition, endothelin can be produced by human and animal airway epithelial cells<sup>12,13</sup>.

A number of investigations have pointed to a role for endothelin in modulating airway responsiveness

and asthmatic reactions<sup>14–16</sup>. As described in the review, endothelin induces a potent contraction in epithelium-denuded tissues. However, it appears that a number of agents that have a contractile action on smooth muscle cause a relaxation when applied to the mucosal side of the airways<sup>1</sup>. Indeed, endothelin induces a NO-dependent relaxation of tracheae that contain epithelium<sup>17</sup>. In a recent study, airway hyperresponsiveness to methacholine was observed in endothelin knock out-mice<sup>18</sup>. Interestingly, NO-synthesis inhibition in endothelin 1 (+/+) wild-type mice significantly enhanced methacholine responsiveness, whereas this pretreatment did not modulate airway responsiveness in endothelin knockout mice<sup>18</sup>. These results support the hypothesis presented in our review that, in asthmatic patients, the airway hyperresponsiveness to a variety of contractile agents might be explained by a diminished production of epithelium-derived relaxing factors<sup>1</sup>.

Finally, it should be concluded that the airway epithelium is more than just a source of epithelium-derived relaxing factors!

**Gert Folkerts and Frans Nijkamp**  
Utrecht Institute for Pharmaceutical Sciences,  
Department of Pharmacology and Pathophysiology,  
PO Box 80082, 3508 TB Utrecht,  
Utrecht University,  
The Netherlands.

### References

- 1 Folkerts, G. and Nijkamp, F. P. (1998) *Trends Pharmacol. Sci.* 19, 334–341
- 2 Reinheimer, T. et al. (1996) *Am. J. Physiol.* 270, L722–L728

- 3 Klapproth, H. *et al.* (1997) *Naunyn-Schmiedeberg's Arch. Pharmacol.* 355, 1–9
- 4 Reinheimer, T., Munch, M., Racké, K., Kirkpatrick, C. J. and Wessler, I. (1998) *Eur. J. Pharmacol.* 349, 277–284
- 5 Wessler, I., Kirkpatrick, C. J. and Racké, K. (1998) *Pharmacol. Ther.* 77, 59–79
- 6 Racké, K., Bähring, A., Brunn, G., Elsner, M. and Wessler, I. (1991) *Br. J. Pharmacol.* 103, 1213–1217
- 7 Holtzman, M. J. (1992) *Annu. Rev. Physiol.* 54, 303–329
- 8 Holtzman, M. J., Zhang, V., Hussain, H., Roswit, W. T. and Wilson, J. D. (1994) *Ann. New York Acad. Sci.* 744, 58–77
- 9 Raeburn, D. (1990) *Gen. Pharmacol.* 21, 11–16
- 10 Watson, N., Magnussen, H. and Rabe, K. F. (1997) *Br. J. Pharmacol.* 121, 1099–1104
- 11 Rennick, R. E., Loesch, A. and Burnstock, G. (1992) *Thorax* 47, 1044–1049
- 12 Shima, H. *et al.* (1995) *Biochem. Mol. Biol. Int.* 37, 1001–1010
- 13 Mullol, J. *et al.* (1996) *Neuropeptides* 30, 551–556
- 14 Redington, A. E. *et al.* (1995) *Am. J. Resp. Crit. Care Med.* 151, 1034–1039
- 15 Chalmers, G. W., Little, S. A., Patel, K. R. and Thomson, N. C. (1997) *Am. J. Resp. Crit. Care Med.* 156, 382–388
- 16 Hay, D. W., Henry, P. J. and Goldie, R. G. (1993) *Trends Pharmacol. Sci.* 14, 29–32
- 17 Filep, J. G., Battistini, B. and Sirois, P. (1993) *Br. J. Pharmacol.* 109, 637–644
- 18 Nagase, T. *et al.* (1998) *Am. J. Resp. Crit. Care Med.* 157, 560–564

## *Trends in Pharmacological Sciences* Receptor and Ion Channel Nomenclature Supplement 1999

by S. P. H. Alexander and J. A. Peters  
10th Edition

The 1999 Receptor and Ion Channel Nomenclature Supplement will be available free to Trends in Pharmacological Sciences subscribers from March 1999. The 10th edition has been significantly expanded, and includes updated and new tables plus the new IUPHAR code; it also contains a glossary of definitions, references and a comprehensive product finder. Several new colour posters that highlight areas of exciting pharmacological study are included.

For further information, please contact:

Thelma Reid, Elsevier Trends Division, 68 Hills Road, Cambridge, UK CB2 1LA.  
Telephone: +44 1223 315961; Fax: +44 1223 464430; E-mail: [t.reid@elsevier.co.uk](mailto:t.reid@elsevier.co.uk)

Elsevier Trends Journals, Subscription Department, PO Box 331,  
Haywards Heath, West Sussex, UK RH16 3FG.  
Tel: +44 1444 475651; Fax: +44 1444 445423;  
E-mail: [etj.subs@rbi.co.uk](mailto:etj.subs@rbi.co.uk)

## Editorial policy

Most articles published in *TiPS* are commissioned by the Editor. However, authors who wish to contribute to any section of the journal should contact the Editor with the names of all authors and a point-by-point outline of the proposed article including 10–12 key references. Outlines may also be sent to members of the Advisory Editorial Board. Completed manuscripts submitted without liaison with the *TiPS* Editorial Office cannot be considered. *TiPS* readers who wish to suggest that a particular topic be covered are also invited to send their suggestions to the Editor.

Correspondence and comment on any aspect of *TiPS* or the field of pharmacology are welcomed and may be sent directly to the Editor.